Hurlocker Margo C, Kirouac Megan, Gillezeau Christina, Hijaz Donia, Moniz-Lewis David I K, Carlon Hannah A, Coleman George Cameron, Ilgen Mark A, Pearson Matthew R, Vowles Kevin E, Witkiewitz Katie
Department of Psychology, Center on Alcohol, Substance Use, and Addictions, University of New Mexico, Albuquerque, USA.
Department of Psychiatry, Michigan Medicine Addiction Treatment Services, University of Michigan, Ann Arbor, MI, USA.
Subst Use Addctn J. 2025 Jan;46(1):192-196. doi: 10.1177/29767342241228126. Epub 2024 Jan 31.
Chronic pain and opioid use disorder (OUD) are public health crises and their co-occurrence has led to further complications and public health impacts. Provision of treatments for comorbid chronic pain and OUD is paramount to address these public health crises. Medications for OUD (MOUD) are gold standard treatments for OUD that have also demonstrated benefit in pain management. However, clinics that provide MOUD for chronic pain or OUD often lack behavioral treatments to address the challenges experienced by individuals with both conditions. Developing and implementing a behavioral treatment that complements MOUD may better equip clinics to provide comprehensive care to the growing proportion of clients who present with comorbid chronic pain and OUD. In the Healing Opioid misuse and Pain through Engagement (HOPE) Trial, we are using an effectiveness-implementation hybrid design to examine the benefits of an integrated behavioral treatment and to determine the feasibility of implementing the integrated treatment into clinics that provide MOUD. The treatment integrated 2 evidence-based treatments-Acceptance and Commitment Therapy and Mindfulness-Based Relapse Prevention-to target the emotional, behavioral, and physiological sequelae of OUD and chronic pain. Implementation feasibility will include assessing changes in implementation readiness and identifying facilitators and barriers to implementing the integrated treatment among all personnel employed in clinics that provide MOUD. This commentary offers an overview of the study and design and details adaptations we made to our study protocol, based largely on clinic personnel time constraints and variable clinic procedures during the COVID-19 pandemic.
慢性疼痛和阿片类药物使用障碍(OUD)是公共卫生危机,它们的同时出现导致了更多并发症和公共卫生影响。为慢性疼痛和OUD共病提供治疗对于应对这些公共卫生危机至关重要。用于治疗OUD的药物(MOUD)是治疗OUD的金标准,在疼痛管理方面也已证明有疗效。然而,为慢性疼痛或OUD提供MOUD的诊所往往缺乏行为治疗,无法应对同时患有这两种疾病的个体所面临的挑战。开发并实施一种能补充MOUD的行为治疗,可能会让诊所更好地为越来越多同时患有慢性疼痛和OUD的患者提供全面护理。在通过参与治愈阿片类药物滥用和疼痛(HOPE)试验中,我们正在采用一种有效性-实施混合设计,以检验综合行为治疗的益处,并确定将这种综合治疗应用于提供MOUD的诊所的可行性。该治疗整合了两种循证治疗方法——接纳与承诺疗法和基于正念的复发预防——来针对OUD和慢性疼痛的情绪、行为和生理后遗症。实施可行性将包括评估实施准备情况的变化,以及确定在提供MOUD的诊所中所有工作人员实施综合治疗的促进因素和障碍。本评论概述了该研究和设计,并详细介绍了我们对研究方案所做的调整,这些调整主要基于COVID-19大流行期间诊所人员的时间限制和可变的诊所程序。